CII
OREX

CR Intrinsic Investors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

CR Intrinsic Investors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-63,923
Closed -$3.92M – 463
2013
Q3 		$3.92M Sell
63,923
-31,537
-33% -$2.14M 0.12% 226
2013
Q2 		$5.58M Buy
+95,460
New +$5.87M 0.19% 167

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CR Intrinsic Investors's OREX Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2013, closing a stake of 63,923 shares — an estimated $3.92M sold.

CR Intrinsic Investors first reported a position in OREX in Q2 2013 and held it in 2 quarters. The position peaked at $5.58M in Q2 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 63,923 Orexigen Therapeutics, Inc. shares in Q4 2013, an estimated $3.92M.
  • CR Intrinsic Investors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • CR Intrinsic Investors's Orexigen Therapeutics, Inc. position peaked at $5.58M in Q2 2013.
  • 124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.